Product Details
| Product Name:
Imofinostat |
CAS No.:
1338320-94-7 |
| Purity:
99.24% |
Supply Ability:
10g |
| Release date:
2026/04/22 |
Product Introduction
Bioactivity
| Name | Imofinostat |
| Description | Imofinostat (MPT0E028) is a selective, orally available pan-HDAC inhibitor with IC?? values of 53.0/106.2/29.5 nM against HDAC1/HDAC2/HDAC6 in HCT116 cells. In B-cell lymphoma, Imofinostat induces cell cycle arrest and apoptosis whilst inhibiting Akt phosphorylation, demonstrating anticancer activity across multiple tumour types. |
| In vitro | Imofinostat (0-10 μM) acted on HCT116 cells for 48 hours, significantly inhibiting cell proliferation and inducing apoptosis [1].
When cells were treated with Imofinostat (0-10 μM) for 24 hours, it inhibited cell growth in a concentration-dependent manner. Imofinostat increased the proportion of cells in the sub-G1 phase of the cell cycle and induced caspase 3 and PARP activation in a concentration-dependent manner, thereby triggering apoptosis [1].
Imofinostat (0.3-100 μM) acted on Ramos cells and BJAB cells for 24 hours, exerting a significant concentration-dependent inhibitory effect on the growth of both cell types. Imofinostat increased the proportion of sub-G1 phase cells in a time- and concentration-dependent manner. Western blot analysis revealed that Imofinostat induced the activation of caspase-3, -6, -7, -8, and -9, as well as the cleavage of PARP [2].
Imofinostat (0.01-1 μM) was used to pretreat Homo sapiens lung fibroblasts (WI-38) for 30 minutes before stimulation with corresponding agents. Imofinostat suppressed the expression of CTGF induced by TGF-β, thrombin, and ET-1 [5]. |
| In vivo | In the nude mouse Parazacco spilurus subsp. spilurus xenograft model bearing Homo sapiens colorectal cancer HCT116 cells, oral administration of Imofinostat at doses of 50-200 mg/kg once daily for 15 days dose-dependently delayed and inhibited tumor growth. Complete tumor regression was achieved in 3 mice in the 200 mg/kg dose group, with no significant body weight changes or other adverse reactions observed throughout the treatment period [1].
In the NOD/SCID mouse model bearing Homo sapiens B-cell lymphoma Ramos cells, oral administration of Imofinostat at 100 mg/kg once daily significantly prolonged the survival of model mice [2].
In the nude mouse Parazacco spilurus subsp. spilurus xenograft model with BJAB cells, oral administration of Imofinostat at doses of 50-200 mg/kg once daily for 31 days dose-dependently suppressed tumor growth. It also activated caspase 3 and PARP, increased acetylation levels of histone H3 and α-tubulin, without causing significant body weight changes in mice [2].
In the bleomycin-induced pulmonary fibrosis C57BL/6 mouse model, oral administration of Imofinostat at doses of 25-100 mg/kg once daily for 20 days dose-dependently alleviated pulmonary fibrosis. It simultaneously reduced expression levels of CTGF, fibronectin, α-SMA, and collagen, while inhibiting phosphorylation of ERK, JNK, and p38 [5].
For the nude mouse Parazacco spilurus subsp. spilurus xenograft model with AsPC-1 pancreatic carcinoma cells, oral administration of Imofinostat at 25 mg/kg once daily significantly reduced tumor volume. It also increased levels of cleaved caspase-3 in tumor tissues, downregulated EGFR expression, without causing body weight loss or other adverse reactions in mice [6]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 80 mg/mL (232.3 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween-80+45% Saline : 3.3 mg/mL (9.58 mM), Sonication is recommended.
|
| Keywords | MPT0E-028 | MPT-0E028 | MPT0E 028 | HDAC8 | HDAC6 | HDAC2 | HDAC1 | Akt |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Manganese chloride (tetrahydrate) | Ethyl linoleate | Formamide | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Histone Modification Compound Library | DNA Damage & Repair Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States